The Observe-and-Plan (O&P) regimen for neovascular age-related macular degeneration (AMD) using aflibercept allows for individualized treatment and reduced injection burden, but real-world adherence to the regimen is inconsistent, according to a study.
Researchers analyzed 561 treatment-naïve eyes that continued to show exudation after the loading dose of intravitreal aflibercept 2 mg. Over 5 follow-up visits, treatment intervals extended from the initial 4-week schedule to a range between 4 and 12 weeks. By the fifth follow-up, 24.9% of eyes were monitored without further treatment, while 49.5% of the remaining 422 eyes adhered to the O&P algorithm.
The researchers concluded that the “O&P treatment regimen leads to a variety of treatment intervals, and some eyes may be overtreated.”
Reference
Turan L, Arnold-Vangsted A, la Cour M, et al. Treatment Interval Progression and Adherence to Observe-and-Plan Regimen for Neovascular Age-Related Macular Degeneration Treated with Aflibercept 2 mg. Ophthalmol Ther. 2025;doi: 10.1007/s40123-025-01095-1. Epub ahead of print. PMID: 39899265.
Related Content
